ARTICLE | Company News
Medicines Co., U.S. Department of Health and Human Services infectious news
October 19, 2015 7:00 AM UTC
HHS’s Biomedical Advanced Research and Development Agency (BARDA) exercised the third option to extend a 2014 contract to develop Carbavance for serious Gram-negative infections. The third award brings the total commitment from BARDA to $53.8 million. The contract is valued at about $90 million over five years if all options are exercised. ...